Development of Large Platelet Aggregates from Small Aggregates as Determined by Laser-light Scattering: Effects of Aggregant Concentration and Antiplatelet Medication

Summary

Particle-counting methods that employ light scattering (LS) quantify changes in the number of platelet aggregates of different sizes after the application of an aggregating stimulus. Using the LS method, we studied the effects of aggregant concentration, aspirin administration, and ticlopidine administration on aggregate formation and compared the results with those obtained using the conventional optical density (OD) method. Subjects were 47 controls, 31 patients treated with aspirin (330 mg/day), and 37 patients treated with ticlopidine (200 mg/day). Platelet aggregation after stimulation by 0.5, 1.0 or 5.0 μM ADP, or 0.5, 1.0 or 2.0 μg/ml collagen was determined using both methods. Using the LS method, small (9-25 μm), medium (25-50 μm), and large (50-70 μm) aggregates were counted. In patients untreated with antiplatelet medication, greater concentrations of ADP or collagen generated larger aggregates. Generation of small and medium-sized aggregates showed a significant positive correlation with OD levels after stimulation with 0.5 or 1.0 μM ADP, or 0.5 or 1.0 μg/ml collagen. In patients treated with aspirin, the development of small aggregates into large aggregates was inhibited. Thus, the number of small aggregates increased. Inhibition induced by aspirin was more effective against aggregation after stimulation with collagen than with ADP. In patients treated with ticlopidine, small and medium-sized aggregate formation was inhibited after stimulation with low concentrations of ADP or collagen, but was promoted after stimulation with high aggregant concentrations. The capability of the LS method to quantify different sizes of aggregates after stimulation with low concentration agonists may facilitate investigation of the aggregation process, and of how this process is affected by antiplatelet agents.

• References

• 1 Bom GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9
• Bom GVR. Observations on the change in shape of blood platelets brought about by adenosine diphoshate. J Physiol 1970; 209: 487-511
• 3 Bom GVR. Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 1967; 215: 1027-9
• 4 Cardinal DL, Flower RJ. The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-58
• 5 Ries H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986; 85: 50-6
• 6 Ingerman-Wojenski C, Smith JB, Silver MJ. Evaluation of electrical aggregometry: platelets. J Lab Clin Med 1983; 101: 44-52
• 7 Nichols AR, Bosmann HB. Platelet aggregation: Newly quantified using nonempirical parameters. Thromb Haemost 1979; 42: 679-93
• 8 Kitek A, Breddin K. Optical density variations and microscopic observations in the evaluation of platelet shape change and microaggregate formation. Thromb Haemost 1980; 44: 154-8
• 9 Gear RL, Lambrecht JK. Reduction in single platelets during primary and secondary aggregation. Thromb Haemost 1981; 45: 298
• 10 Latimer P, Bom GVR, Michal F. Application of light-scattering theory to the optical effects associated with the morphology of blood platelets. Arch Biochem Biophys 1977; 180: 151-9
• 11 Born GVR, Deamley R, Foulks JG, Sharp DE. Quantification of the morphological reaction of platelets to aggregating agents and its reversal by aggregation inhibitors. J Physiol 1978; 280: 193-212
• 12 Latimer P. Blood platelet aggregometry: The proposed use of scattered instead of transmitted light. Biophys J 1984; 45: 21 a
• 13 Hantgan RR. A study of kinetics and mechanism of ADP-triggered platelet aggregation. Biochim Biophys Acta 1985; 846: 64-75
• 14 Hubbell JA, Pohl PI, Wagner WR. The use of laser-light scattering and controlled shear in plateletaggregometry. Thromb Haemost 1991; 65: 601-7
• 15 Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284-294
• 16 Kamiguian A, Grelac F, Levy-Toledano S, Legrand YJ, Rendu F. Collagen-induced platelet activation mainly involves the protein kinase C pathway. Biochem J 1990; 268: 325-331
• 17 Nakano T, Hanasaki K, Arita H. Possible involvement of cytoskeleton in collagen-stimulated activation of phospholipases in human platelets. J Biol Chem 1989; 264: 5400-5406
• 18 Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262
• 19 Ashida S-I, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemost 1979; 41: 436-449
• 20 Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-338
• 21 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit J Med 1994; 308: 081-106
• 22 Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, Kusakabe K. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989; 20: 1643-1647